Expression of matrix metalloproteinase 2 and 9 in experimentally wounded canine corneas and spontaneous chronic corneal epithelial defects

Cornea

Volumn 26, Issue 10, 2007, Pages 1213-1219

  Carter, Renee T ^a   Kambampati, Ravi ^a   Murphy, Christopher J ^a   Bentley, Ellison ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Canine; Cornea; Matrix metalloproteinase; Recurrent erosion; Zymography

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA INJURY; DEBRIDEMENT; DOG; IMMUNOHISTOCHEMISTRY; KERATECTOMY; KERATINOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; ZYMOGRAPHY;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; CORNEA; CORNEAL DISEASES; DEBRIDEMENT; DISEASE MODELS, ANIMAL; DOGS; EPITHELIUM, CORNEAL; EYE INJURIES; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; UP-REGULATION; WOUND HEALING;

EID: 36549052710     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31814b8a28     Document Type: Article

References (42)

1. Heyworth P, Morlet N, Rayner S, et al. Natural history of recurrent erosion syndrome - a 4 year review of 117 patients. Br J Ophthalmol. 1998;82:26-28.
2. Murphy C, Marfurt C, McDermott A, et al. Spontaneous chronic corneal epithelial defects (SCCED) in dogs: clinical features, innervation, and effect of topical SP, with or without IGF-1. Invest Ophthalmol Vis Sci. 2001;42:2252-2261.
3. Cook C, Wilcock B. A Clinical and Histopathologic Study of Canine Persistent Corneal Ulcers. 26th Annual Meeting of the American College of Veterinary Ophthalmologists, RI, September 27-30, 1995:139.
4. Stanley R, Hardman C, Johnson B. Results of grid keratotomy, superficial keratectomy and debridement for the management of persistent corneal erosions in 92 dogs. Vet Ophthalmol. 1998;1:233-238.
5. Kirschner S, Niyo Y, Betts D. Idiopathic persistent corneal erosions: clinical and pathological findings in 18 dogs. J Am Anim Hosp Assoc. 1989;25:84-90.
6. Bentley E, Abrams G, Covitz D, et al. Morphology and immunohistochemistry of spontaneous chronic corneal epithelial defects (SCCED) in dogs. Invest Ophthalmol Vis Sci. 2001;42:2262-2269.
7. Rubinfeld R. Recurrent erosion syndromes. In: Krachmer J, Mannis M, Holland E, eds. Cornea. 1st ed. St. Louis: Mosby; 1997:1317-1326.
8. Morgan R, Abrams K. A comparison of six different therapies for persistent corneal erosions in dogs and cats. Vet Ophthalmol. 1994;4:38-43.
9. Goldmann J, Dohlman C, Kravitt B. The basement membrane of the human cornea in recurrent epithelial erosion syndrome. Trans Am Acad Ophthalmol Otolaryngol. 1969;73:471-481.
10. Isakow I, Romem M, Dabush S, et al. Posttraumatic recurrent corneal erosion. 1. Clinical and histological studies. Metab Pediatr Syst Ophthalmol. 1982;6:349-353.
11. Tripathi RC, Bron AJ. Ultrastructural study of non-traumatic recurrent corneal erosion. Br J Ophthalmol. 1972;56:73-85.
12. Rosenberg M, Tervo T, Petroll W, et al. In vivo confocal microscopy of patients with corneal recurrent erosion syndrome or epithelial basement membrane dystrophy. Ophthalmology. 2000;107:565-573.
13. Messer G, Isakow I, Dabush S, et al. Posttraumatic recurrent corneal erosion, #2. Ultrastructural findings in epithelium and stroma. Metab Pediatr Syst Ophthalmol. 1983;7:59-66.
14. Bentley E, Campbell S, Woo H, et al. The effect of chronic corneal epithelial debridement on epithelial and stromal morphology in dogs. Invest Ophthalmol Vis Sci. 2002;43:2136-2142.
15. Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen. 1999;7:423-432.
16. Matsubara M, Girard M, Kublin C, et al. Differential roles for two gelatinolytic enzymes of the matrix metalloproteinase family in the remodeling cornea. Dev Biol. 1991;147:425-439.
17. Matsubara M, Zieske J, Fini M. Mechanism of basement membrane dissolution preceding corneal ulceration. Invest Ophthalmol Vis Sci. 1991;32:3221-3237.
18. Mohan R, Chintala S, Jung J, et al. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. J Biochem (Tokyo). 2002;277:2065-2072.
19. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123-2133.
20. Mulholland B, Tuft SJ, Khaw PT. Matrix metalloproteinase distribution during early corneal wound healing. Eye. 2005;19:584-588.
21. Murphy G, Ward R, Hembry RM, et al. Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J. 1989;258:463-472.
22. Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques. 2005;38:73-83.
23. Gerona M, Zieske J, Assouline M, et al. Matrix metalloproteinases in epithelia from human recurrent corneal erosions. Invest Ophthalmol Vis Sci. 1999;40:1266-1270.
24. Daniels J, Geerling G, Alexander R, et al. Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue. Exp Eye Res. 2003;77:653-664.
25. Sobrin L, Liu Z, Monroy D, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci. 2000;41:1703-1709.
26. Alfonso A, Sobrin L, Monroy D, et al. Tear fluid gelatinase B activity correlates with IL-1a concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci. 1999;40:2506-2512.
27. Dursun D, Kim M, Solomon A, et al. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol. 2001;132:8-13.
28. Smith VA, El-Rakhawy A, Easty DL. Matrix metalloproteinase 2 activation in cultured corneas. Ophthalmic Res. 2001;33:1-6.
29. Hirayama K, Yokota H, Onai R, et al. Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. J Comp Pathol. 2002;127:249-256.
30. Leibman NF, Lana SE, Hansen RA, et al. Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. J Vet Intern Med. 2000;14:583-586.
31. Fini ME, Girard MT, Matsubara M, et al. Unique regulation of the matrix metalloproteinase, gelatinase B. Invest Ophthalmol Vis Sci. 1995;36:622-633.
32. Fini ME, Girard MT, Matsubara M. Collagenolytic/gelatinolytic enzymes in corneal wound healing. Acta Ophthalmol (Copenh). 1992;70:26-33.
33. Fini ME, Parks WC, Rinehart WB, et al. Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am J Pathol. 1996;149:1287-1302.
34. Bannikov GA, Karelina TV, Collier IE, et al. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J Biol Chem. 2002;277:16022-16027.
35. Mirastschijski U, Impola U, Jahkola T, et al. Ectopic localization of matrix metalloproteinase 9 in chronic cutaneous wounds. Hum Pathol. 2002;33:355-364.
36. Cook H, Stephens P, Davies KJ, et al. Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity. J Invest Dermatol. 2000;115:225-233.
37. Saghizadeh M, Brown DJ, Castellon R, et al. Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas. A possible mechanism of basement membrane and integrin alterations. Am J Pathol. 2001;158:723-734.
38. Woo HM, Bentley E, Campbell SF, et al. Nerve growth factor and corneal wound healing in dogs. Exp Eye Res. 2005;80:633-642.
39. Wilson SE, Liang Q, Kim WJ. Lacriman gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 1999;40:2185-2190.
40. Okada Y, Eible G, Guha S, et al. Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin and Exper Metast. 2004;21:285-292.
41. Khan KMF, Falcone DJ, Kraemer R. Nerve growth factor activation of Erk-1 and Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle cells. J Bio Chem. 2002;277:2353-2359.
42. Liu Z, Klominek J. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax. 2003;58:198-203.